MARKET

AVRO

AVRO

AVROBIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.23
+0.19
+1.32%
Opening 14:46 01/22 EST
OPEN
14.06
PREV CLOSE
14.04
HIGH
14.40
LOW
13.55
VOLUME
196.35K
TURNOVER
--
52 WEEK HIGH
29.32
52 WEEK LOW
9.76
MARKET CAP
589.61M
P/E (TTM)
-4.3177
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit
AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen 202...
Business Wire · 7h ago
AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer
Business Wire · 3d ago
AVROBIO to Present at the ICR Conference 2021
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present virtually at the ICR Conference 2021 at 1...
Business Wire · 01/08 12:00
Is AVRO A Good Stock To Buy Now?
Insider Monkey · 12/16/2020 15:46
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares ...
BusinessWire · 12/04/2020 09:00
AVROBIO Announces Closing of Underwritten Public Offering
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock. The aggregate gross proceeds to the company from the ...
Business Wire · 11/24/2020 21:19
AVROBIO Announces Closing of Underwritten Public Offering
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock. The aggregate gross proceeds to the company from the offering, before deducting underwriting discounts and commission and estimated offering expenses, totaled $75 million. As previously announced, the company has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
BusinessWire · 11/24/2020 18:19
AVROBIO Announces Closing of Underwritten Public Offering
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock. The aggregate gross proceeds to the company from the ...
BusinessWire · 11/24/2020 18:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVRO. Analyze the recent business situations of AVROBIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVRO stock price target is 36.71 with a high estimate of 58.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 156
Institutional Holdings: 37.99M
% Owned: 91.65%
Shares Outstanding: 41.45M
TypeInstitutionsShares
Increased
24
2.15M
New
24
50.74K
Decreased
40
1.73M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.73%
Pharmaceuticals & Medical Research
+0.79%
Key Executives
Chairman/Independent Director
Bruce Booth
President/Chief Executive Officer/Director
Geoff MacKay
President/Chief Executive Officer/Director
Geoffrey MacKay
Chief Financial Officer/Chief Accounting Officer/Treasurer
Erik Ostrowski
Corporate Executive
Birgitte Volck
Chief Technology Officer
Kim Raineri
Other
Deanna Petersen
Secretary
Steven Avruch
Director
Gail Farfel
Independent Director
Ian Clark
Other
Holly May
Independent Director
Phillip Donenberg
Independent Director
Annalisa Jenkins
Independent Director
Christopher Paige
Independent Director
Philip Vickers
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AVRO
AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.
More

Webull offers kinds of Avrobio Inc stock information, including NASDAQ:AVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVRO stock methods without spending real money on the virtual paper trading platform.